Last Updated : February 14, 2025
Details
Generic Name:
risankizumab
Project Status:
Pending
Therapeutic Area:
Ulcerative colitis
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Skyrizi
Project Line:
Reimbursement Review
Project Number:
SR0890-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy or advanced therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : February 14, 2025